Federated Hermes, Inc. Evolus, Inc. Transaction History

Federated Hermes, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$9.99 - $14.91 $322,447 - $481,250	32,277 Added 76850.0%	32,319 $452,000
Q4 2023 Jan 31, 2024	BUY	$7.6 - $10.53 $319 - $442	42 New	42 $0
Q2 2022 Aug 15, 2022	SELL	$10.22 - $13.94 $331,598 - $452,297	-32,446 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$5.22 - $11.78 $671,234 - $1.51 Million	-128,589 Reduced 79.85%	32,446 $364,000
Q4 2021 Feb 14, 2022	SELL	$5.37 - $8.38 $724 - $1,131	-135 Reduced 0.08%	161,035 $1.05 Million
Q3 2021 Nov 15, 2021	BUY	$7.36 - $13.67 $66,666 - $123,822	9,058 Added 5.95%	161,170 $1.23 Million
Q2 2021 Aug 16, 2021	BUY	$8.42 - $13.96 $962,911 - $1.6 Million	114,360 Added 302.92%	152,112 $1.92 Million
Q1 2021 May 13, 2021	BUY	$3.2 - $16.51 $120,806 - $623,285	37,752 New	37,752 $490,000
Q1 2019 May 10, 2019	SELL	$12.43 - $28.91 $6,724 - $15,640	-541 Closed	0 $0
Q4 2018 Feb 13, 2019	SELL	$10.57 - $19.29 $613 - $1,118	-58 Reduced 9.68%	541 $6,000
Q3 2018 Nov 13, 2018	BUY	$17.31 - $29.82 $10,368 - $17,862	599 New	599 $11,000

168

47.8M

130K

51K

Ticker EOLS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 56,094,800
Market Cap $561M
Description
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorp...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.